Literature DB >> 23328489

Effect of the expression of BRCA2 on spontaneous homologous recombination and DNA damage-induced nuclear foci in Saccharomyces cerevisiae.

Laura Spugnesi1, Cristina Balia, Anita Collavoli, Elisabetta Falaschi, Valentina Quercioli, Maria Adelaide Caligo, Alvaro Galli.   

Abstract

The tumour-suppressor gene BRCA2 has been demonstrated to be involved in maintenance of genome integrity by affecting DNA double-strand break repair and homologous recombination. Protein-truncating mutations in BRCA2 predispose women to early onset breast and ovarian cancers and account for 15-30% of familial breast cancer risk. In contrast, the human cancer risk due to missense mutations, intronic variants, and in-frame deletions and insertions in the BRCA2 gene, called unclassified variants, has not been determined. Here, we want to define if the yeast Saccharomyces cerevisiae is a good model to study the role of BRCA2 in DNA recombination and repair and to characterise the unclassified BRCA2 missense variants. Therefore, we expressed the wild-type BRCA2 in yeast and determined the effect of BRCA2 on yeast homologous recombination, methyl methanesulphonate (MMS)-induced Rad51 and Rad52 foci and MMS sensitivity. The expression of BRCA2 induces a high increase in both intra- and inter-recombination events and confers a higher MMS resistance as compared with the negative control. This may suggest that BRCA2 gets involved in DNA repair pathways in yeast. Moreover, the expression of BRCA2 did not affect the number of cells carrying Rad51 or Rad52 nuclear foci. Finally, we aimed to investigate if yeast could be reliable system to set up a functional assay to distinguish a mutated protein from a neutral polymorphism. Therefore, we have expressed two neutral (M1915T and A2951T) and one pathogenic variant (G2748D) in yeast and checked the effect on recombination. The neutral M1915T variant increased intra-chromosomal recombination by almost 2-fold and the other neutral A2975T variant increased intra-chromosomal recombination 2.5-fold as compared with the control. On the other end, the pathogenic variant G2748D did not increase intra- and inter-chromosomal recombination in yeast and, consequently, confers a phenotype very different from the wild-type BRCA2. Moreover, we have also evaluated whether the expression of the selected unclassified variants affects homologous recombination in yeast. Results indicated that the expression of the selected BRCA2 variants differentially affects yeast recombination suggesting that yeast could be a very promising genetic system to characterise BRCA2 missense variants.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23328489     DOI: 10.1093/mutage/ges069

Source DB:  PubMed          Journal:  Mutagenesis        ISSN: 0267-8357            Impact factor:   3.000


  9 in total

1.  Yeast as a Model to Unravel New BRCA2 Functions in Cell Metabolism.

Authors:  Alessandra Costanza; Nicoletta Guaragnella; Antonella Bobba; Caterina Manzari; Alberto L'Abbate; Claudio Lo Giudice; Ernesto Picardi; Anna Maria D'Erchia; Graziano Pesole; Sergio Giannattasio
Journal:  Front Oncol       Date:  2022-06-06       Impact factor: 5.738

Review 2.  Molecular contribution of BRCA1 and BRCA2 to genome instability in breast cancer patients: review of radiosensitivity assays.

Authors:  Fatemeh Sadeghi; Marzieh Asgari; Mojdeh Matloubi; Maral Ranjbar; Nahid Karkhaneh Yousefi; Tahereh Azari; Majid Zaki-Dizaji
Journal:  Biol Proced Online       Date:  2020-10-01       Impact factor: 3.244

Review 3.  Functional assays for analysis of variants of uncertain significance in BRCA2.

Authors:  Lucia Guidugli; Aura Carreira; Sandrine M Caputo; Asa Ehlen; Alvaro Galli; Alvaro N A Monteiro; Susan L Neuhausen; Thomas V O Hansen; Fergus J Couch; Maaike P G Vreeswijk
Journal:  Hum Mutat       Date:  2013-12-03       Impact factor: 4.878

Review 4.  A comprehensive analysis of BRCA2 gene: focus on mechanistic aspects of its functions, spectrum of deleterious mutations, and therapeutic strategies targeting BRCA2-deficient tumors.

Authors:  Anjali Shailani; Raman Preet Kaur; Anjana Munshi
Journal:  Med Oncol       Date:  2018-01-31       Impact factor: 3.064

5.  Globally Rare BRCA2 Variants With Founder Haplotypes in the South African Population: Implications for Point-of-Care Testing Based on a Single-Institution BRCA1/2 Next-Generation Sequencing Study.

Authors:  Jaco Oosthuizen; Maritha J Kotze; Nicole Van Der Merwe; Ettienne J Myburgh; Phillip Bester; Nerina C van der Merwe
Journal:  Front Oncol       Date:  2021-02-12       Impact factor: 6.244

Review 6.  Saccharomyces cerevisiae as a Model System for Eukaryotic Cell Biology, from Cell Cycle Control to DNA Damage Response.

Authors:  Laura Vanderwaeren; Rüveyda Dok; Karin Voordeckers; Sandra Nuyts; Kevin J Verstrepen
Journal:  Int J Mol Sci       Date:  2022-10-01       Impact factor: 6.208

7.  Multiple gene sequencing for risk assessment in patients with early-onset or familial breast cancer.

Authors:  Po-Han Lin; Wen-Hung Kuo; Ai-Chu Huang; Yen-Shen Lu; Ching-Hung Lin; Sung-Hsin Kuo; Ming-Yang Wang; Chun-Yu Liu; Fiona Tsui-Fen Cheng; Ming-Hsin Yeh; Huei-Ying Li; Yu-Hsuan Yang; Yu-Hua Hsu; Sheng-Chih Fan; Long-Yuan Li; Sung-Liang Yu; King-Jen Chang; Pei-Lung Chen; Yen-Hsuan Ni; Chiun-Sheng Huang
Journal:  Oncotarget       Date:  2016-02-16

8.  Stimulation of homologous recombination in plants expressing heterologous recombinases.

Authors:  Abdellah Barakate; Ewan Keir; Helena Oakey; Claire Halpin
Journal:  BMC Plant Biol       Date:  2020-07-16       Impact factor: 4.215

Review 9.  Imprecise Medicine: BRCA2 Variants of Uncertain Significance (VUS), the Challenges and Benefits to Integrate a Functional Assay Workflow with Clinical Decision Rules.

Authors:  Judit Jimenez-Sainz; Ryan B Jensen
Journal:  Genes (Basel)       Date:  2021-05-20       Impact factor: 4.096

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.